Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521

Watchlist Manager
Zhejiang Huahai Pharmaceutical Co Ltd Logo
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Watchlist
Price: 17.57 CNY 1.04% Market Closed
Market Cap: 25.5B CNY
Have any thoughts about
Zhejiang Huahai Pharmaceutical Co Ltd?
Write Note

Zhejiang Huahai Pharmaceutical Co Ltd
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang Huahai Pharmaceutical Co Ltd
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang Huahai Pharmaceutical Co Ltd
SSE:600521
Common Stock
ÂĄ1.5B
CAGR 3-Years
-1%
CAGR 5-Years
3%
CAGR 10-Years
6%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Common Stock
ÂĄ52k
CAGR 3-Years
0%
CAGR 5-Years
120%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Common Stock
ÂĄ603.3m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
14%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Common Stock
ÂĄ6.4B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
16%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Common Stock
ÂĄ1.8B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Common Stock
ÂĄ401m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Huahai Pharmaceutical Co Ltd
Glance View

Market Cap
25.8B CNY
Industry
Pharmaceuticals

Zhejiang Huahai Pharmaceutical Co. Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Taizhou, Zhejiang and currently employs 7,019 full-time employees. The company went IPO on 2003-03-04. The firm's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine hydrochloride tablets, risperidone tablets, fosinopril sodium tablets, as well as irbesartan and hydrochlorothinzide tablets, among others. The firm also provides related technical support services. The firm distributes its products in domestic and overseas markets.

Intrinsic Value
25.58 CNY
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Zhejiang Huahai Pharmaceutical Co Ltd's Common Stock?
Common Stock
1.5B CNY

Based on the financial report for Jun 30, 2024, Zhejiang Huahai Pharmaceutical Co Ltd's Common Stock amounts to 1.5B CNY.

What is Zhejiang Huahai Pharmaceutical Co Ltd's Common Stock growth rate?
Common Stock CAGR 10Y
6%

Over the last year, the Common Stock growth was -1%. The average annual Common Stock growth rates for Zhejiang Huahai Pharmaceutical Co Ltd have been -1% over the past three years , 3% over the past five years , and 6% over the past ten years .

Back to Top